Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Current Assets (2018 - 2025)

Nanobiotix has reported Current Assets over the past 8 years, most recently at $73.0 million for Q4 2025.

  • For Q4 2025, Current Assets rose 11.21% year-over-year to $73.0 million; the TTM value through Dec 2025 reached $73.0 million, up 11.21%, while the annual FY2025 figure was $73.0 million, 11.21% up from the prior year.
  • Current Assets for Q4 2025 was $73.0 million at Nanobiotix, up from $45.2 million in the prior quarter.
  • Over five years, Current Assets peaked at $139.5 million in Q2 2021 and troughed at $36.6 million in Q2 2023.
  • A 5-year average of $77.8 million and a median of $75.4 million in 2022 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: plummeted 52.9% in 2023 and later soared 136.61% in 2024.
  • Year by year, Current Assets stood at $106.5 million in 2021, then crashed by 49.82% to $53.4 million in 2022, then surged by 75.92% to $94.0 million in 2023, then tumbled by 30.1% to $65.7 million in 2024, then rose by 11.21% to $73.0 million in 2025.
  • Business Quant data shows Current Assets for NBTX at $73.0 million in Q4 2025, $45.2 million in Q2 2025, and $65.7 million in Q4 2024.